Media ReleasesImmutep

View All Immutep News

Recruitment of stage 1 of part B in TACTI-002 study complete

• 23 patients with second line Non-Small Cell Lung Cancer (NSCLC) participating in Stage 1, Part B
• Total of 87 patients out of up to 109 patients (80%) are enrolled and participating in the trial, with recruitment continuing for stage 2 of Part C at present
• Further data from TACTI-002 expected throughout calendar year 2020

For more information, please download the attached PDF
Download this document